- $3.53m
- $26.92m
- $59.37m
- 50
- 96
- 44
- 68
2019 September 30th | R2020 September 30th | 2021 September 30th | R2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 39.3 | 43.5 | 43.1 | 45 | 59.4 |
Cost of Revenue | |||||
Gross Profit | 15.6 | 17.6 | 17 | 16.6 | 25.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 46.7 | 48.1 | 51.9 | 59.2 | 60.9 |
Operating Profit | -7.45 | -4.57 | -8.74 | -14.1 | -1.51 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.6 | -7.36 | 0.769 | -10.8 | -6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.3 | -9.43 | 0.394 | -10.6 | -6.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -22.4 | -10.5 | -7.81 | -13 | -9.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -24.3 | -10.5 | -7.81 | -13.2 | -9.52 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -213 | -35.2 | 0.874 | -11.8 | -7.68 |